TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18403559
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no intravenous rtPA)
Study: 8829858
Drug: Ketorolac 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 0.4 mg.kg‐1 iv, repeated three times at six hour intervals
Study: 8829858
Drug: Diclofenac 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 1.0 mg.kg‐1 iv after general anaesthesia induction and 1.0 mg.kg‐1 after 12 hr
Study: 2809260
Drug: Intraventricular gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraventricular gentamicin therapy
Study: 2809260
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics alone
Study: 31790151
Drug: Aspirin added
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin added to adjuvant chemotherapy
Study: 31790151
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to adjuvant chemotherapy
Study: 21654128
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (LDA) in high-risk group
Study: 21654128
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (LDA) in low-risk group
Study: 7923842
Drug: Antibiotics added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics added to treatment by sinus lavage
Study: 7923842
Drug: Sinus lavage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinus lavage without antibiotics
Study: 406098
Drug: Oral isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral isosorbide dinitrate (ISDN) 29 mg
Study: 31299067
Drug: Ritonavir-boosted darunavir
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir-boosted darunavir monotherapy for 48 weeks
Study: 26097039
Drug: ustekinumab 45
Normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: ustekinumab 45 mg
Study: 26097039
Drug: ustekinumab 90
Normalized name: ustekinumab 90 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: ustekinumab 90 mg
Study: 26097039
Drug: ustekinumab 45
Normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: ustekinumab 45 mg and 90 mg
Study: 22230809
Drug: continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuation of current therapy (C group, n=20)
Study: 15842550
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg morphine sulphate (M)
Study: 15842550
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg oxycodone hydrochloride (O)
Study: 15842550
Drug: Combination M10/O5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination M10/O5
Study: 15842550
Drug: Combination M7.5/O7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination M7.5/O7.5
Study: 15842550
Drug: Combination M5/O10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination M5/O10
Study: 15168720
Drug: Once-daily didanosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily didanosine (ddI)
Study: 15168720
Drug: Twice-daily stavudine
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily stavudine (d4T) plus once-daily ddI
Study: 7808252
Drug: Overtraining group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overtraining group (OT) - exercised daily for 2 weeks at 100% of 1 RM
Study: 2780876
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of chlorpromazine (CPZ)
Study: 31180512
Drug: Mandibular advancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular advancement splint (MAS) + oral EPAP
Study: 31180512
Drug: Mandibular advancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular advancement splint (MAS) + oral/nasal EPAP
Study: 24118671
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg lomitapide on Day 1 followed by 200 mg on Day 3
Study: 24118671
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg BID
Study: 24118671
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg moxifloxacin on Day 3
Study: 11122838
Drug: Rituximab (unconjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (unconjugated anti-CD20 monoclonal antibody)
Study: 11122838
Drug: Cytokines (e.g.,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokines (e.g., interferon-alpha, interleukin-2, interleukin-12)
Study: 11122838
Drug: Vaccine strategies
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine strategies
Study: 9062869
Drug: Melatonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin treatment (0.5 mg at bedtime for 7 days)
Study: 9062869
Drug: Melatonin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin treatment (50 mg daily at bedtime for 37 days)
Study: 8366176
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg cyclosporine
Study: 8366176
Drug: Aspirin 960
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 960 mg three times daily
Study: 8366176
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of cyclosporine and aspirin
Study: 26936601
Drug: Immune-enhancing dietary
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune-enhancing dietary supplement for 7 days before and 5 days after surgery
Study: 26936601
Drug: Immune-enhancing dietary
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune-enhancing dietary supplement
Study: 7787157
Drug: Nizatidine 150
Normalized name: nizatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 150 mg h.s.
Study: 538766
Drug: Aspartame in
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame in solution (100 mg/kg body weight)
Study: 538766
Drug: Aspartame in
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame in slurry (100 mg/kg body weight)
Study: 538766
Drug: Aspartame in
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame in solution and slurry (100 mg/kg body weight)
Study: 25993805
Drug: Compound DCR
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound DCR (1.8 g · d(‐1))
Study: 25993805
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (75 mg · d(‐1))
Study: 24261608
Drug: Micafungin 100
Normalized name: micafungin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin 100 mg intravenously once a day for 14 days
Study: 19696660
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of 75% fucoidan capsules for 12 days
Study: 19696660
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g of guar gum capsules for 12 days
Study: 10475182
Drug: Tenecteplase (30-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenecteplase (30-50 mg according to body weight)
Study: 10475182
Drug: Alteplase (<=
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (<= 100 mg)
Study: 8557121
Drug: Purified FSH
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified FSH preparations
Study: 8557121
Drug: Strategies for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strategies for OHSS prevention (intravenous albumin, triggering with GnRH-a, withholding menotropin therapy)
Study: 6175803
Drug: Alinidine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alinidine 40 mg once daily
Study: 6175803
Drug: Alinidine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alinidine 40 mg twice daily
Study: 21898040
Drug: Pentoxifylline (PTX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (PTX), 400 mg/tid from 24 h before to 24 h after coronary angioplasty
Study: 21898040
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with routine treatment and no PTX
Study: 18822413
Drug: Extended-release (ER)
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release (ER) niacin 1000 mg/day
Study: 16255470
Drug: COX‐2 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: COX‐2 inhibitors (COX‐2i)
Study: 12501222
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg twice daily plus omeprazole 20 mg daily
Study: 2649340
Drug: Premeal injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premeal injections of short‐acting insulin and intermediate‐acting insulin at bedtime (using Novopen)
Study: 2649340
Drug: Conventional three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional three times daily injection regimen
Study: 334207
Drug: Anidoxime 75
Normalized name: obidoxime
DrugBank: Obidoxime (DB13750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anidoxime 75 mg
Study: 334207
Drug: Anidoxime 100
Normalized name: obidoxime
DrugBank: Obidoxime (DB13750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anidoxime 100 mg
Study: 334207
Drug: Dihydrocodeine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrocodeine 50 mg
Study: 27136904
Drug: Ethinyl estradiol/gestodene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinyl estradiol/gestodene contraceptive patch
Study: 8680050
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous corticosteroids (i.v. steroids) and conventional triple therapy
Study: 1740541
Drug: Transdermal delivery
Normalized name: nitroglycerin 5 mg in 1 d TRANSDERMAL PATCH [Nitroglycerin Transdermal Delivery System]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal delivery system (TDS) with 20 mg GTN, applied for 4 successive days
Study: 1740541
Drug: Transdermal delivery
Normalized name: nitroglycerin 5 mg in 1 d TRANSDERMAL PATCH [Nitroglycerin Transdermal Delivery System]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal delivery system (TDS) releasing 15 mg GTN/day
Study: 1740541
Drug: Transdermal delivery
Normalized name: nitroglycerin 5 mg in 1 d TRANSDERMAL PATCH [Nitroglycerin Transdermal Delivery System]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal delivery system (TDS)
Study: 1740541
Drug: Sublingually administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingually administered GTN
Study: 28513525
Drug: Exercise with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise with soft tissue manipulation therapy
Study: 28513525
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (triple therapy of needle, moxibustion, and cupping jar)
Study: 19464558
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated H7N3 virus vaccine (10^7.5 TCID50 administered by nasal spray, 2 doses, 5 weeks apart)
Study: 19464558
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated H7N3 virus vaccine (first dose)
Study: 19464558
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated H7N3 virus vaccine (second dose)
Study: 19464558
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated H7N3 virus vaccine
Study: 12047396
Drug: Nateglinide 60
Normalized name: nateglinide 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 60 mg plus metformin 1000 mg b.i.d.
Study: 12047396
Drug: Nateglinide 120
Normalized name: nateglinide 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 120 mg plus metformin 1000 mg b.i.d.
Study: 12047396
Drug: Nateglinide 120
Normalized name: nateglinide 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 120 mg plus metformin 1000 mg b.i.d. in patients with HbA1c > 9.5%.
Study: 12047396
Drug: Nateglinide 60
Normalized name: nateglinide 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide 60 mg in patients with low HbA1c levels (<or= 8%) at baseline.
Study: 22050786
Drug: Metformin 1000
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1000 mg b.i.d.
Study: 12361194
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg o.d.
Study: 11317199
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Losartan + Enalapril)
Study: 9207352
Drug: 15% undecylenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% undecylenic acid cream
Study: 3304029
Drug: Ketanserin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (mean dose 167 mg/day)
Study: 18655558
Drug: Fulu Baoxinping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulu Baoxinping (FLBXP) oral liquid 10 mL thrice a day for 28 days
Study: 18655558
Drug: Wenxin Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wenxin Granule 9 g thrice a day for 28 days
Study: 15936933
Drug: BUD/F (2x100/6
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD/F (2x100/6 microg) administered in the evening (2000 h)
Study: 20837588
Drug: Dexamethasone (moderately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (moderately early treatment)
Study: 20837588
Drug: Dexamethasone (delayed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (delayed treatment)
Study: 9344701
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of serological marker (anti-GAD) and genetic marker (HLA-DRB1)
Study: 26773777
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) capsules at a dose of 1 g total catechin, primarily gallated type
Study: 26773777
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) capsules
Study: 25262522
Drug: Danhong injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danhong injection 20 ml
Study: 25262522
Drug: Blood producing
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood producing needle 400 mg (Control)
Study: 25262522
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between experimental group and control group after treatment
Study: 22475545
Drug: plasma exchange
Approvals — FDA: no, EMA: no, PMDA: no
Description: plasma exchange (as adjunctive therapy)
Study: 20078491
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg nicotine yield cigarettes
Study: 20078491
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg nicotine yield cigarettes
Study: 31658113
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg nicotine lozenge
Study: 15776771
Drug: Tazarotene 0.1%
Normalized name: TAZAROTENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.1% cream, once daily for 12 weeks
Study: 15776771
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% cream, once daily for 12 weeks
Study: 12463291
Drug: Metformin (specialists)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (specialists)
Study: 12463291
Drug: Metformin (generalists)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (generalists)
Study: 12463291
Drug: Alpha1-blockers (specialists)
Normalized name: Thymosin alpha1 (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha1-blockers (specialists)
Study: 12463291
Drug: Alpha1-blockers (generalists)
Normalized name: Thymosin alpha1 (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha1-blockers (generalists)
Study: 8835620
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of mefloquine 1250 mg
Study: 8835620
Drug: Divided doses
Normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided doses of mefloquine (750 mg and 500 mg at 6-h intervals)
Study: 6119182
Drug: Chlorthalidone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (100 mg/day)
Study: 6119182
Drug: Chlorthalidone +
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone + beta-blocker
Study: 6119182
Drug: Chlorthalidone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (100 mg/day) in subgroup IA (11 men)
Study: 6119182
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of beta-blocker in subgroup IB (5 men, 2 post-menopausal women)
Study: 6119182
Drug: Clopamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopamide (5 mg/day) in group II (18 men)
Study: 6119182
Drug: Clopamide +
Normalized name: clopamide
DrugBank: Clopamide (DB13792)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopamide + pindolol (10 mg/day)
Study: 22010913
Drug: Earlier ART
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Earlier ART (2 weeks after starting tuberculosis treatment)
Study: 22010913
Drug: Later ART
Approvals — FDA: no, EMA: no, PMDA: no
Description: Later ART (8 weeks after starting tuberculosis treatment)
Study: 14674053
Drug: Nefazodone (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (up to 600 mg daily)
Study: 10965288
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy by allocation
Study: 10965288
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy by preference
Study: 8981691
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of betaxolol (0.25%) and pilocarpine (1.75%), used 3 times daily in Studies 1 and 2; 2 times daily in Study 3.
Study: 8981691
Drug: Betaxolol (0.25%)
DrugBank: Betaxolol (DB00195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaxolol (0.25%) alone, used 3 times daily in Studies 1 and 2; 2 times daily in Study 3.
Study: 8981691
Drug: Pilocarpine (1.75%)
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine (1.75%) alone, used 3 times daily in Studies 1 and 2; 2 times daily in Study 3.
Study: 8981691
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of betaxolol and pilocarpine with surfactant, used 2 times daily in Study 3.
Study: 1289101
Drug: SK plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SK plus Heparin
Study: 3905057
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy with exercise-induced angina
Study: 3905057
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy with exercise-induced angina
Study: 25174776
Drug: iopromide 370
Normalized name: IOPROMIDE 370mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopromide 370 mgI/mL
Study: 25174776
Drug: iopromide 300
Normalized name: IOPROMIDE 300mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopromide 300 mgI/mL
Study: 22884306
Drug: Family focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family focused treatment for adolescents (FFT‐A)
Study: 22884306
Drug: Enhanced care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced care (a briefer psychoeducational treatment)
Study: 15623998
Drug: Bonding agent
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bonding agent (Syntac) with amalgam
Study: 15623998
Drug: Amalgam with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amalgam with adhesive resin luting agent (Resinomer)
Study: 7626876
Drug: Cold blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold blood intermittent cardioplegia plus topical ice slush in hypothermic CPB
Study: 11644558
Drug: Randomised controlled
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomised controlled trial treatment protocol
Study: 19231043
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 200 mg
Study: 16768834
Drug: Soya isoflavones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soya isoflavones (50 mg/d)
Study: 12963609
Drug: Docosahexaenoic acid
Normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docosahexaenoic acid supplementation (400 mg/d)
Study: 12086759
Drug: High-dose BEAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose BEAM and transplantation of haemopoietic stem cells (BEAM‐HSCT)
Study: 12086759
Drug: Overall survival
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall survival for both treatments
Study: 31899499
Drug: Home exercise
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home exercise intervention delivered by a physical therapist with 6 home visits over 8 months and monthly calls, exercising ≥3 times weekly
Study: 29667763
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg (open-label)
Study: 22241704
Drug: Home-based constraint-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based constraint-induced therapy
Study: 20937130
Drug: NGX-4010 (8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGX-4010 (8% capsaicin patch)
Study: 20937130
Drug: 0.04% capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04% capsaicin control patch